Aspects of the invention are directed to methods of stimulating or promoting neurogenesis by administering to a subject of a composition comprising a cyclodextrin and a polyethylene glycol to alleviate learning, memory and cognitive deficits present in subjects afflicted with various brain disorders or from neurodegenerative disorder associated with aging.

Aspects of the invention are directed to methods of stimulating or promoting neurogenesis by administering to a subject of a composition comprising a cyclodextrin and a polyethylene glycol to alleviate learning, memory and cognitive deficits present in subjects afflicted with various brain disorders or from neurodegenerative disorder associated with aging.

The present invention relates to bulk dry compositions comprising polyethylene glycol and an additive, such as a flavoring agent and/or sweetener, wherein the additive remains at a consistent concentration throughout the bulk composition. The invention also relates to processes for preparing the bulk dry compositions comprising polyethylene glycol.

The present invention relates to bulk dry compositions comprising polyethylene glycol and an additive, such as a flavoring agent and/or sweetener, wherein the additive remains at a consistent concentration throughout the bulk composition. The invention also relates to processes for preparing the bulk dry compositions comprising polyethylene glycol.

The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.

The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.

The present invention comprises compounds of formula (I): where R.sup.1 may be PEG or other polymeric moieties. For example, R.sup.1 may be repeating PEG units —(CH.sub.2—CH.sub.2—O).sub.n—, wherein n=1-455. R.sup.1 may also be other polymeric moieties of varying sizes and structures, for example, R.sup.1 may be poly(glycolide), poly(lactic acid), poly(lactide), poly(caprolactone), poly(lactide-co-caprolactone), poly(lactide-co-glycolide), or poly(lactic acid)-butanol. One or more embodiments of the invention may also relate to injectable pharmaceutical compositions comprising polymer conjugated monomethyl fumarate, and methods for treating relapsing-remitting multiple sclerosis and psoriasis. ##STR00001##

The present invention comprises compounds of formula (I): where R.sup.1 may be PEG or other polymeric moieties. For example, R.sup.1 may be repeating PEG units —(CH.sub.2—CH.sub.2—O).sub.n—, wherein n=1-455. R.sup.1 may also be other polymeric moieties of varying sizes and structures, for example, R.sup.1 may be poly(glycolide), poly(lactic acid), poly(lactide), poly(caprolactone), poly(lactide-co-caprolactone), poly(lactide-co-glycolide), or poly(lactic acid)-butanol. One or more embodiments of the invention may also relate to injectable pharmaceutical compositions comprising polymer conjugated monomethyl fumarate, and methods for treating relapsing-remitting multiple sclerosis and psoriasis. ##STR00001##

The present invention relates to a hydrogel composition prepared without using a binder. The composition is easy to inject into the human body and has a therapeutic effect on intraarticular lesions and inflammation. The hydrogel of the present invention, which is prepared without a binder, is degraded in an articulation for a long time due to the increased viscoelasticity thereof, thereby enjoying the advantage that the absorption time is prolonged. Therefore, when the hydrogel is used as an injection, its efficacy may be maintained for a long time. Furthermore, the hydrogel has no cytotoxicity, thus showing very high biocompatibility. Particularly when directly injected to an injured site in an articulation, the hydrogel has a therapeutic effect on the intraarticular lesion and inflammation in the corresponding site and thus may be advantageously utilized as a composition for prevention or treatment of an intraarticular lesion and as a viscosity supplement.

The present invention relates to a hydrogel composition prepared without using a binder. The composition is easy to inject into the human body and has a therapeutic effect on intraarticular lesions and inflammation. The hydrogel of the present invention, which is prepared without a binder, is degraded in an articulation for a long time due to the increased viscoelasticity thereof, thereby enjoying the advantage that the absorption time is prolonged. Therefore, when the hydrogel is used as an injection, its efficacy may be maintained for a long time. Furthermore, the hydrogel has no cytotoxicity, thus showing very high biocompatibility. Particularly when directly injected to an injured site in an articulation, the hydrogel has a therapeutic effect on the intraarticular lesion and inflammation in the corresponding site and thus may be advantageously utilized as a composition for prevention or treatment of an intraarticular lesion and as a viscosity supplement.